Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
| Autor: | Ronald G. Stoller, William C. Zamboni, David M. Friedland, Sakkaraiappan Ramalingam, Robert P. Edwards, S. Strychor, Lauren J. Maruca, Ramesh K. Ramanathan, Beth A. Zamboni, Chandra P. Belani, Huali Wu |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Drug media_common.quotation_subject Pharmacology Polyethylene Glycols Pharmacokinetics Neoplasms Humans Medicine Pharmacology (medical) In patient Infusions Intravenous Aged media_common Liposome business.industry Age Factors Cancer Middle Aged medicine.disease Antineoplastic Agents Phytogenic Phase i study Clinical trial Prior Therapy Liposomes Body Composition Camptothecin Female business |
| Zdroj: | Clinical Pharmacology & Therapeutics. 86:519-526 |
| ISSN: | 1532-6535 0009-9236 |
| DOI: | 10.1038/clpt.2009.141 |
| Popis: | S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients > or =60 years of age have a 2.7-fold higher exposure of S-CKD602 as compared with patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text